Jupiter Neurosciences, Inc. Common Stock (JUNS) — Cash Flow-to-Debt Ratio
Jupiter Neurosciences, Inc. Common Stock (JUNS) has a Cash Flow-to-Debt Ratio of -0.56x as of June 2026, meaning its operating cash flow of $-2.29 Million could theoretically repay -1% of its total liabilities ($4.08 Million) in one year. See Jupiter Neurosciences, Inc. Common Stock (JUNS) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jupiter Neurosciences, Inc. Common Stock Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Jupiter Neurosciences, Inc. Common Stock across 7 annual periods. For the full cash flow conversion analysis, see Jupiter Neurosciences, Inc. Common Stock operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Jupiter Neurosciences, Inc. Common Stock (2019–2025)
Year-by-year debt coverage analysis for Jupiter Neurosciences, Inc. Common Stock. Check Jupiter Neurosciences, Inc. Common Stock (JUNS) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.73x | $-5.41 Million | $7.40 Million | ▲ +62.0% |
| 2024 | -1.93x | $-3.91 Million | $2.03 Million | ▼ -2283.0% |
| 2023 | -0.08x | $-480.95K | $5.95 Million | ▲ +52.2% |
| 2022 | -0.17x | $-1.25 Million | $7.38 Million | ▲ +43.0% |
| 2021 | -0.30x | $-1.74 Million | $5.85 Million | ▼ -396.4% |
| 2020 | -0.06x | $-254.78K | $4.26 Million | ▼ -110.1% |
| 2019 | -0.03x | $-142.95K | $5.02 Million | — |